ARS Pharmaceuticals, Inc logo

ARS Pharmaceuticals, Inc(SPRY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.96
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SPRY

11/20/2026: SPRY (1-star) is currently NOT-A-BUY. Pass it for now.

ARS Pharmaceuticals is a commercial-stage biopharmaceutical company best known for its flagship product, neffy, a pioneering needle-free intranasal epinephrine spray for treating severe allergic reactions. The company's primary business strength lies in its first-mover advantage and proprietary absorption technology, which offer a convenient alternative to traditional auto-injectors and are driving rapid revenue growth. Its core investment story centers on converting needle-phobic patients and capturing expanding market share globally. However, key risks include heavy product concentration, ongoing operating losses, and potential insurance reimbursement hurdles. The stock suits growth-oriented investors willing to tolerate biotech volatility while monitoring ongoing sales adoption and formulary coverage developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveRapid top-line revenue expansion and high market potential make it attractive for growth strategies.
Momentum investorMixed fitMomentum fit is conditional on a positive price breakout and sustained upward technical momentum.
Value investorWeak fitThe absence of current earnings or positive free cash flow makes it unsuited for traditional value metrics.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into commercial growth.
Low-risk investorWeak fitHigh clinical, commercial, and price volatility characteristics conflict with low-risk objectives.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings based on commercial milestones and market sentiment.
Valuation riskMedium / highValuation relies heavily on long-term projections of neffy adoption rather than current earnings.
Competition risk (traditional auto-injectors)MediumEntrenched legacy device manufacturers pose ongoing market adoption hurdles.
Business qualityMediumThe company features a high-value proprietary product but lacks broad multi-product diversification.
Dividend incomeLow / noneNo cash distributions are provided to shareholders.
Execution riskHighSuccess depends heavily on effective commercial scaling and securing favorable insurance coverage.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 297.56M USD
Price to earnings Ratio -
1Y Target Price 17
Price to earnings Ratio -
1Y Target Price 17
Volume (30-day avg) 2.2M shares
Beta 1.16
52 Weeks Range 2.44 - 13.15
Updated Date 11/21/2026
52 Weeks Range 2.44 - 13.15
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.01

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -19.2%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SPRY receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SPRY has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-2241.8%), weak cash generation (FCF margin -203.1%), negative revenue growth (-5.5%).

Financial Health Rating

★★★★★
SPRY's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 75.0%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
SPRY's growth profile is soft, with the least-weak measure being revenue growth at -5.5% FY2025 versus FY2024. By comparison, while earnings growth (-2241.8%, negative) and free-cash-flow growth (-1418.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 89.1% and approximately 48.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 16.01% supports management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 10.83%
Rubric Capital Management LP 8.52%
Orbimed Advisors LLC 8.27%
Deerfield Management Co 7.49%
BlackRock Inc 5.30%

Unit Economics (Per $1K Revenue)

★★★★★
SPRY generates approximately $758 of gross profit, $-2,129 of operating income, and $-2,031 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.05%

Quantitative Style Profile

★★★★★
SPRY has a Short Squeeze Candidate profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Product Sales - neffy (United States)Direct commercial sales of neffy for the emergency treatment of Type I allergic reactions in the U.S.This is the primary engine driving top-line revenue growth.
International Partnerships & LicensingMilestone payments and royalties from commercialization partners distributing neffy (EURneffy) overseas.Provides secondary capital streams and expands global reach without heavy direct operational spend.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 281.02M
Price to Sales(TTM) 2.44
Enterprise Value 281.02M
Price to Sales(TTM) 2.44
Enterprise Value to Revenue 2.3
Enterprise Value to EBITDA -9.88
Shares Outstanding 100.53M
Shares Floating 49.12M
Shares Outstanding 100.53M
Shares Floating 49.12M
Percent Insiders 16.01
Percent Institutions 89.1

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.